Cargando…

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

BACKGROUND: To evaluate the immunomodulating and clinical effects of nilotinib, a tyrosine kinase inhibitor, in a proof-of-concept study in spondyloarthritis (SpA) assessing the mast cell as potential novel therapeutic target in this disease. METHODS: Twenty eight patients with active peripheral (pS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paramarta, Jacqueline E., Turina, Maureen C., Noordenbos, Troy, Heijda, Tanja F., Blijdorp, Iris C., Yeremenko, Nataliya, Baeten, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081668/ https://www.ncbi.nlm.nih.gov/pubmed/27784336 http://dx.doi.org/10.1186/s12967-016-1050-2

Ejemplares similares

Serum biomarkers to predict clinical response in proof-of-concept trials in spondyloarthritis
por: Turina, Maureen, et al.
Publicado: (2011)

Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis
por: Turina, Maureen C, et al.
Publicado: (2014)

Identification of robust and disease-specific stromal alterations in spondyloarthritis synovitis
por: Yeremenko, Nataliya, et al.
Publicado: (2011)

IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
por: Noordenbos, Troy, et al.
Publicado: (2011)

IL-17 in spondyloarthritis: is the T-party over?
por: Yeremenko, Nataliya, et al.
Publicado: (2011)

A psychometric analysis of outcome measures in peripheral spondyloarthritis
por: Turina, Maureen C, et al.
Publicado: (2016)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

IL-17A producing mast cells as therapeutic target in spondyloarthritis
por: Yeremenko, N, et al.
Publicado: (2010)

Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis
por: Paramarta, Jacqueline E, et al.
Publicado: (2011)

Expansion of Interleukin‐22– and Granulocyte–Macrophage Colony‐Stimulating Factor–Expressing, but Not Interleukin‐17A–Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis
por: Blijdorp, Iris C. J., et al.
Publicado: (2019)

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
por: Paramarta, Jacqueline E, et al.
Publicado: (2014)

Altered cytokine expression by macrophages from HLA-B27-positive spondyloarthritis patients without evidence of endoplasmic reticulum stress
por: Ambarus, Carmen A, et al.
Publicado: (2018)

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
por: de Winter, Janneke J, et al.
Publicado: (2019)

Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis
por: Barthel, Christian, et al.
Publicado: (2009)

Relative overexpression of membrane-bound versus soluble TNF in spondyloarthritis
por: Ambarus, Carmen A, et al.
Publicado: (2012)

Transmembrane TNF drives osteoproliferative joint inflammation reminiscent of human spondyloarthritis
por: Kaaij, Merlijn H., et al.
Publicado: (2020)

Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis
por: Yeremenko, Nataliya
Publicado: (2021)

The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?
por: Omarjee, Loukman, et al.
Publicado: (2017)

Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis
por: Cañete, Juan D., et al.
Publicado: (2015)

An add-on training program involving breathing exercises, cold exposure, and meditation attenuates inflammation and disease activity in axial spondyloarthritis – A proof of concept trial
por: Buijze, G. A., et al.
Publicado: (2019)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis
por: Ambarus, Carmen A, et al.
Publicado: (2012)

Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
por: Alshiekh‐Nasany, Ruham, et al.
Publicado: (2016)

Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib
por: Leitão, Juliana Ribeiro, et al.
Publicado: (2016)

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
por: Kim, T-M, et al.
Publicado: (2011)

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
por: Ananthula, Hari Krishna, et al.
Publicado: (2018)

Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy
por: Hussain, Tariq, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
por: Gordon, Jessica, et al.
Publicado: (2011)

The window of opportunity: a relevant concept for axial spondyloarthritis
por: Robinson, Philip C, et al.
Publicado: (2014)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo
por: van Kuijk, Arno W. R., et al.
Publicado: (2010)

The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist
por: Burgos-Vargas, Ruben
Publicado: (2012)

The Versatile Transceiver Proof of Concept
por: Troska, J, et al.
Publicado: (2009)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis
por: Carracedo, Miguel, et al.
Publicado: (2022)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

The role of Bob1 in rheumatoid arthritis: potential implications for autoimmunity
por: Yeremenko, Nataliya, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nc05nfpgd3gvso81957j1gkgut